These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 27186120)

  • 1. Investigational agents in the treatment of Parkinson's disease: focus on safinamide.
    Malek NM; Grosset DG
    J Exp Pharmacol; 2012; 4():85-90. PubMed ID: 27186120
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safinamide in the management of patients with Parkinson's disease not stabilized on levodopa: a review of the current clinical evidence.
    Bette S; Shpiner DS; Singer C; Moore H
    Ther Clin Risk Manag; 2018; 14():1737-1745. PubMed ID: 30271159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safinamide as Add-On Therapy to Levodopa in Mid- to Late-Stage Parkinson's Disease Fluctuating Patients: Post hoc Analyses of Studies 016 and SETTLE.
    Cattaneo C; Sardina M; Bonizzoni E
    J Parkinsons Dis; 2016; 6(1):165-73. PubMed ID: 26889632
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safinamide as an Adjunct to Levodopa in Asian and Caucasian Patients With Parkinson's Disease and Motor Fluctuations: A Post Hoc Analysis of the SETTLE Study.
    Bhidayasiri R; Ishida T; Kamei T; Husni RE; Suzuki I; Wu SL; Cho JW
    J Mov Disord; 2023 May; 16(2):180-190. PubMed ID: 37096301
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real life evaluation of safinamide effectiveness in Parkinson's disease.
    Mancini F; Di Fonzo A; Lazzeri G; Borellini L; Silani V; Lacerenza M; Comi C
    Neurol Sci; 2018 Apr; 39(4):733-739. PubMed ID: 29441484
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year, randomized, controlled study of safinamide as add-on to levodopa in mid to late Parkinson's disease.
    Borgohain R; Szasz J; Stanzione P; Meshram C; Bhatt MH; Chirilineau D; Stocchi F; Lucini V; Giuliani R; Forrest E; Rice P; Anand R;
    Mov Disord; 2014 Sep; 29(10):1273-80. PubMed ID: 25044402
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A systematic review and meta-analysis of safety and efficacy of safinamide for motor fluctuations in patients with Parkinson's disease.
    Abdelalem Aziz Ahmed M
    F1000Res; 2019; 8():2078. PubMed ID: 32431802
    [No Abstract]   [Full Text] [Related]  

  • 8. Emerging approaches in Parkinson's disease - adjunctive role of safinamide.
    Müller T
    Ther Clin Risk Manag; 2016; 12():1151-60. PubMed ID: 27536120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switching from Rasagiline to Safinamide as an Add-On Therapy Regimen in Patients with Levodopa: A Literature Review.
    Sanchez Alonso P; De La Casa-Fages B; Alonso-Cánovas A; Martínez-Castrillo JC
    Brain Sci; 2023 Feb; 13(2):. PubMed ID: 36831820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic drug evaluation of safinamide mesylate for the treatment of mid-to-late stage Parkinson's disease.
    Müller T
    Expert Opin Drug Metab Toxicol; 2017 Jun; 13(6):693-699. PubMed ID: 28537214
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Safinamide Mesilate (Equfina
    Koebisu M; Ishida T
    Nihon Yakurigaku Zasshi; 2020; 155(4):269-276. PubMed ID: 32612042
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safinamide: A Review in Parkinson's Disease.
    Blair HA; Dhillon S
    CNS Drugs; 2017 Feb; 31(2):169-176. PubMed ID: 28110399
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-Term Effects of Safinamide on Dyskinesia in Mid- to Late-Stage Parkinson's Disease: A Post-Hoc Analysis.
    Cattaneo C; Ferla RL; Bonizzoni E; Sardina M
    J Parkinsons Dis; 2015; 5(3):475-81. PubMed ID: 26406127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sustained response in early responders to safinamide in patients with Parkinson's disease and motor fluctuations: A
    Bhidayasiri R; Koebis M; Kamei T; Ishida T; Suzuki I; Cho JW; Wu SL
    Front Neurol; 2023; 14():1147008. PubMed ID: 37051060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant therapies for Parkinson's disease: critical evaluation of safinamide.
    Stocchi F; Torti M
    Drug Des Devel Ther; 2016; 10():609-18. PubMed ID: 26917951
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effects of Safinamide Adjunct Therapy on Depression and Apathy in Patients With Parkinson's Disease:
    Hattori N; Kogo Y; Koebis M; Ishida T; Suzuki I; Tsuboi Y; Nomoto M
    Front Neurol; 2021; 12():752632. PubMed ID: 35222225
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of safinamide adjunct therapy on pain in patients with Parkinson's disease: Post hoc analysis of a Japanese phase 2/3 study.
    Tsuboi Y; Koebis M; Kogo Y; Ishida T; Suzuki I; Nomoto M; Hattori N
    J Neurol Sci; 2021 Oct; 429():118070. PubMed ID: 34509801
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An expert opinion on safinamide in Parkinson's disease.
    Onofrj M; Bonanni L; Thomas A
    Expert Opin Investig Drugs; 2008 Jul; 17(7):1115-25. PubMed ID: 18549347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study.
    Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H
    Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and pharmacodynamics of safinamide, a neuroprotectant with antiparkinsonian and anticonvulsant activity.
    Marzo A; Dal Bo L; Monti NC; Crivelli F; Ismaili S; Caccia C; Cattaneo C; Fariello RG
    Pharmacol Res; 2004 Jul; 50(1):77-85. PubMed ID: 15082032
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.